Last reviewed · How we verify
Furfurylmethylamphetamine (FURFENOREX)
Furfurylmethylamphetamine (generic name: FURFENOREX) is a furfenorex drug. It is currently in Phase 2 development.
Furfenorex is believed to work by inhibiting the reuptake of certain neurotransmitters in the brain.
Furfurylmethylamphetamine, also known as Furfenorex, is a small molecule drug of the furfenorex class. Its original development and current ownership are unknown. Furfenorex's target and approved indications are also unknown, and it has not been approved by the FDA. The commercial status of Furfenorex is unclear, and key safety considerations are unavailable. Further research is needed to understand this compound's pharmacology and clinical applications.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
CNS / neurology attrition
-3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | FURFENOREX |
|---|---|
| Drug class | furfenorex |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | Phase 2 |
| Annual revenue | 172 |
Mechanism of action
Imagine your brain is a busy city with many messengers (neurotransmitters) carrying important information. Furfenorex helps keep these messengers in the city longer, allowing them to have a greater impact on the brain's functions.
Approved indications
Common side effects
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Furfurylmethylamphetamine CI brief — competitive landscape report
- Furfurylmethylamphetamine updates RSS · CI watch RSS
Frequently asked questions about Furfurylmethylamphetamine
What is Furfurylmethylamphetamine?
How does Furfurylmethylamphetamine work?
What is the generic name of Furfurylmethylamphetamine?
What drug class is Furfurylmethylamphetamine in?
What development phase is Furfurylmethylamphetamine in?
What is Furfurylmethylamphetamine's annual revenue?
Related
- Drug class: All furfenorex drugs
- Therapeutic area: All drugs in Neuroscience
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing